Vol. 3, No. 6 — June 2026Independent since 2024

TheCompound Journal

Reporting on incretins, compounding & the peptide supply chain

A monthly journal of record.
30 issues · 32 contributors
Not medical advice. We sell nothing.

Provenance

A document, not a test: what a certificate actually is

The header identifies the batch, the table records the tests, and the footer says who is answerable. Two of the three are usually incomplete.

A certificate of analysis is not a test result. It is a statement, made by whoever signs it, that a defined quantity of material identified by a batch number was subjected to defined tests by defined methods and produced results within defined limits on a defined date. Every element of that sentence is load-bearing, and a document missing any of them is not a weak certificate but a different kind of object: an assertion of quality with no way back to the evidence. The Journal has read several hundred of these and the distribution is not encouraging, though the reason is more mundane than the trade’s more excitable commentary suggests.

A certificate is a document, not a test

The confusion at the root of almost every dispute about certificates is a category error. A certificate of analysis is not a measurement. It is a record asserting that measurements were made, by named methods, on identified material, on a stated date, with stated outcomes, and that somebody reviewed and released the batch on that basis. The measurements exist elsewhere: in instrument data files, in analyst notebooks, in a laboratory information system. The certificate is the summary that travels with the goods.

This distinction has a practical consequence. When the Journal wants to know whether a purity figure is sound, we do not scrutinise the certificate; we ask for the underlying laboratory report and, where possible, the chromatogram. The certificate can only tell us what somebody concluded. The chromatogram tells us what the instrument saw, and the two are separated by decisions about integration, thresholds and reporting that the certificate does not record.

It follows that a certificate’s value is almost entirely a function of whether it can be traced back to that underlying evidence. A document with a batch number, a date, a named method and a named analyst is checkable in principle even if nobody ever checks it. A document with a percentage and a logo is not checkable by anyone, including the company that issued it, and the difference between those two situations is invisible to a buyer who reads only the number.

The header block: identifying the object

The top of a certificate answers the question, what is this document about. A complete header names the product, gives a catalogue or item number, gives the batch or lot number, states the quantity or fill weight, names the manufacturer and the site, and identifies the customer or order where applicable. Some add a chemical name, a sequence in single-letter code, a molecular formula and a molecular weight, all of which are useful because they let a reader check the theoretical values used elsewhere on the page.

The sequence in particular is worth insisting on. A certificate that prints the one-letter sequence has given a reader the means to calculate the expected mass independently, and therefore to check the identity line. Two of the twenty companies in the Journal’s dossier programme do this as standard. It costs nothing and it converts one line of the document from an assertion into a verifiable claim.

What a header should never do is identify the product only by a trade name. A vial described as a proprietary blend with no chemical identity, no formula and no sequence cannot be checked against anything, and a certificate for such a product is a document about a name. This is a documentary observation rather than an accusation, and the remedy is trivial: print the sequence.

The analytical work behind these products is often better than the paperwork that reports it.

On why a bad document is not a bad product

The test table: four columns, and most certificates carry two

The body of a certificate is a table, and a complete one has four columns: the test performed, the method used, the specification applied, and the result obtained. Four columns, one row per test. That structure is not a convention peculiar to pharmaceuticals; it is what a record of controlled testing looks like in any field, because each column answers a question the other three cannot.

The method column is where the detail belongs — not the word HPLC but a method identifier, a gradient, a wavelength, a column chemistry. The specification column states what the batch had to achieve. The result column states what it did. A certificate carrying only test and result has dropped the two columns that make the result interpretable, and this is by far the commonest structural deficiency the Journal encounters.

The compendial framework for validating an analytical procedure exists precisely to establish that a stated method can discriminate what it claims to discriminate, which is why a method reference is not bureaucratic ornament but the hook on which everything else hangs.12 A named method can be looked up, compared, criticised and repeated. An unnamed one cannot be, and a result generated by one is a number whose provenance stops at the page.

Documentary discrepancies in 63 certificates audited by the Journal
FindingCertificatesResolved on enquiryUnresolved
Batch number absent from the vial itself19145
No specification column for one or more tests17116
Method stated only as an acronym1697
Date of manufacture absent13103
No name in the signature block1174
Expiry date with no supporting stability data963
Molecular weight inconsistent with printed sequence330
Chromatogram identical to one on another document211
Sixty-three certificates supplied to the Journal between the first quarter of 2025 and the second quarter of 2026, covering the twenty companies in the dossier programme and eleven others. “Resolved on enquiry” means the company supplied an explanation or corrected document that the standards desk accepted. No finding in this table is presented as evidence of misconduct by any company.

Water, counter-ion and the mass in the vial

A lyophilised peptide is not pure peptide even when it is chromatographically pure. It is a salt, usually of trifluoroacetic or acetic acid, containing residual water that a hygroscopic powder acquires readily, and sometimes residual solvent from purification. Three lines on a certificate address this and they are usually absent: water content, counter-ion identity and content, and residual solvent.

Water is determined by Karl Fischer titration or by loss on drying, and the pharmacopoeial methods for it are old, settled and inexpensive.3 A peptide containing eight per cent water by mass contains eight per cent less peptide than its label implies, and the figure is not stable: it depends on how the vial was stoppered and how long it has been open. Counter-ion content is a larger contribution still for basic peptides purified in trifluoroacetic acid, where the counter-ion fraction can reach ten to twenty per cent of total mass.4

Put these together and the practical statement is the one this department repeats: the nominal mass on a research vial is an upper bound on the peptide it contains, not a value. A certificate that reports purity and is silent on water and counter-ion has told you the material is clean and nothing at all about how much of it there is.

The ten-minute check

Minute one: find the batch number on the certificate and find it on the vial. Not the carton. If they do not match, or the vial has no number, stop and ask the supplier what the relationship is. Minutes two and three: find the date of manufacture and the date of analysis, and compute the interval. Then compute the interval between the date of analysis and today.

Minutes four and five: read the test table and count the columns. If the specification column is missing, the results cannot be assessed. If the method column is missing or says only HPLC, the purity figure cannot be compared with anybody else’s. Minute six: check the identity line for a theoretical mass, and check whether the convention — monoisotopic or average — is stated. Minute seven: read the signature block for a name and a role.

Minutes eight to ten: list what is not there. Content, water, counter-ion, residual solvent, endotoxin, sterility. Then decide whether any of those matter for what you are doing, which is a question only the reader can answer. The exercise does not establish that a certificate is right or wrong. It establishes whether the document can be checked at all, and in the Journal’s experience roughly a third of certificates in general circulation fail before minute five. Readers who work through this and find something they cannot interpret are welcome to write to standards@compoundjournal.com.

109856137132024 audit2026 audit7143060120180365days between manufacture and analysiscumulative % of certificates
Figure. Cumulative share of audited certificates whose date of analysis falls within a given number of days of manufacture, comparing the Journal’s 2024 audit with the 2026 cycle. Documents missing either date are excluded from both series.

What remains genuinely absent from this market is any documentation of what happens to a vial between the date of analysis and the day it is opened. Every certificate is a snapshot at manufacture; nothing records the four months in transit and storage that follow. Until somebody prices a cheap release-and-receipt check, the honest statement about any research vial is that its purity was measured once, some time ago, by a method that may not be stated.

References

  1. United States Pharmacopeia. General chapter ⟨1225⟩, Validation of Compendial Procedures. USP–NF.
  2. International Council for Harmonisation. Q2(R2): Validation of Analytical Procedures. 2023.
  3. European Directorate for the Quality of Medicines. European Pharmacopoeia, general chapter 2.5.12, “Water: semi-micro determination.” Strasbourg.
  4. “Residual trifluoroacetate in synthetic peptide preparations: quantitation, salt exchange and the effect on nominal mass.” Journal of Peptide Science. 2016;22(11):702–710.

Letters to the Editor

2 printed

Selected from correspondence received on this article. Writers are identified by initial, surname and city, verified before printing. Replies are from the desk that filed the piece or from the standards editor. Write to letters@compoundjournal.com.

You put every documentary finding to the company before publication, which is admirable and also means you are letting companies that do not reply escape coverage entirely. Silence should have a cost.

P. Vuković, Split

The Journal replies

It does, and we should make it more visible. Non-response is recorded in the dossier register and published there. What we will not do is publish an inference we cannot support merely because nobody objected to it, and that constraint does protect the unresponsive. We accept the trade knowingly.

A technical query on your identity row: you specify 4111.1 Da monoisotopic with a tolerance of ±10 ppm, which is 0.04 daltons. Is that not tighter than most contract laboratories will commit to on a peptide of that size?

L. Marulanda, Medellín

The Journal replies

It is achievable on an orbital trap with internal calibration and is tight for a quadrupole time-of-flight on external calibration. The row is drawn from a real certificate issued by a laboratory running the former. We should have said so, and the note now does.

Related coverage